Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients

Figure 1 Distribution of breast cancer gene mutations and homologous recombination deficiency in breast and ovarian cancers. Among breast cancer patients, 17.7% (10/57) harbored pathogenic mutations in germline BRCA1 (gBRCA1), while 8.7% (5/57) had mutations in gBRCA2. In the ovarian cancer group, 8% (2/25) of patients had gBRCA1 mutations, 4% (1/25) had gBRCA2 mutations, and 12% (3/25) had homologous recombination deficiency.